Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Catalyst Pharmaceuticals Inc. (CPRX) saw its stock price increase by 1.17% to $24.98 on Monday, a strong trading day for the overall stock market. The company's shares closed 6.02% below its 52-week high. The NASDAQ Composite and Dow Jones Industrial Average also experienced gains.
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
Zacks Equity Research highlights the recovery of the drug and biotech sector since mid-2025, driven by strong quarterly results, M&A activity, and pipeline successes. The industry faces challenges like patent expirations but is benefiting from innovation, AI in drug discovery, and sustained M&A. Five companies—Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics—are identified as strong additions to investors' portfolios due to their promising prospects and positive developments.
Is It Too Late To Consider Catalyst Pharmaceuticals (CPRX) After Strong Multi Year Rerating?
This article analyzes Catalyst Pharmaceuticals (CPRX) from a valuation perspective, concluding that the stock appears undervalued. Using a Discounted Cash Flow (DCF) model, the estimated intrinsic value is US$63.46 per share, implying a 61.1% discount from its current trading price of US$24.69. Additionally, its P/E ratio of 14.07x is below the biotech industry average and its own Fair Ratio of 14.89x, further suggesting it is moderately undervalued.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Catalyst Pharmaceuticals Inc. (CPRX) saw its stock price increase by 4.12% to $24.76 on Tuesday, outperforming the broader market. This rise occurred during a strong trading session where the NASDAQ Composite Index and Dow Jones Industrial Average also made significant gains. This marks the second day of consecutive gains for the company's stock.
JPMorgan Chase & Co. Sells 54,915 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
JPMorgan Chase & Co. reduced its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 12.7% in Q3, selling 54,915 shares and now owning 378,807 shares valued at approximately $7.46 million. Despite this, analysts maintain a "Strong Buy" consensus rating with a $34 price target, following recent upgrades. Catalyst Pharmaceuticals is a small-cap biopharma company specializing in rare neuromuscular diseases, with a market cap of $2.9 billion and significant institutional ownership.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Catalyst Pharmaceuticals Inc. (CPRX) saw its stock advance by 1.62% to $23.78 on Monday, outperforming the overall mixed market session. The company's shares closed 10.53% below its 52-week high of $26.58. This performance occurred while the Dow Jones Industrial Average rose and the NASDAQ Composite Index fell.
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Mixed Long Term And Recent Shareholder Returns
Catalyst Pharmaceuticals (CPRX) has shown mixed stock performance recently, with long-term gains but short-term declines. Despite this, the company exhibits a P/E ratio of 13.3x, suggesting undervaluation compared to industry peers and its own fair P/E estimate. A Discounted Cash Flow (DCF) model by Simply Wall St further implies a significant discount, with a fair value of $63.97 per share against its current price of $23.40.
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Catalyst Pharmaceuticals Inc. (CPRX) stock declined by 3.51% on Friday, closing at $23.40. This underperformance occurred during a generally negative trading day for the market, with both the NASDAQ Composite and Dow Jones Industrial Average also seeing significant drops. The stock's fall ended a two-day winning streak.
Truist Financial Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to "Strong-Buy"
Truist Financial has upgraded Catalyst Pharmaceuticals (NASDAQ:CPRX) to a "Strong-Buy" rating, aligning with Zacks and contributing to a consensus price target of $34.00. The biopharmaceutical company's stock trades within a one-year range of $19.05–$26.58, and it holds a market capitalization of $2.91 billion. Institutional investors show significant confidence, with 79.22% of the stock currently owned by hedge funds and other institutional investors.
Vanguard realigns reporting; Catalyst Pharmaceuticals (CPRX) shows 0% ownership
The Vanguard Group has filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Catalyst Pharmaceuticals (CPRX). This change is due to an internal realignment at Vanguard, effective January 12, 2026, where certain subsidiaries will now report beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing clarifies that this is an administrative change reflecting reporting structure adjustments rather than a change in investment strategy or an economic sale.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Catalyst Pharmaceuticals Inc. (CPRX) rose 1.89% to $24.25 on Thursday, despite a difficult trading day for the broader market. This marks the second consecutive day of gains for the stock, outperforming the NASDAQ Composite and Dow Jones Industrial Average which both fell. The article highlights CPRX's resilience amidst competitors' declines.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Catalyst Pharmaceuticals Inc. (CPRX) saw its stock price rise by 3.16% to $23.80 on a strong trading day, outpacing broader market indices like the NASDAQ Composite and Dow Jones Industrial Average. This performance occurred despite the stock being 10.46% below its 52-week high reached in June.
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Catalyst Pharmaceuticals Inc. (CPRX) saw its stock decline by 1.07% to $23.07 on Tuesday, performing worse than the overall market. This drop ended a two-day winning streak for the company, as both the NASDAQ Composite Index and Dow Jones Industrial Average also experienced declines.
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)
This article provides a technical analysis of Catalyst Pharmaceuticals Inc. (CPRX), noting its overall technical rating of 3 out of 10. While the short-term trend is negative, the long-term trend remains neutral. Key support and resistance levels are identified, and various technical indicators like RSI and MACD are analyzed, generally suggesting a neutral to negative short-term outlook.
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum Cooldown
Catalyst Pharmaceuticals (CPRX) has seen its share price momentum cool recently, with mixed returns despite solid financials. The company is currently trading at a P/E of 13x, which positions it as undervalued compared to its peers (32.5x) and the broader US biotechs industry (16.7x), and even below an estimated fair P/E of 16x. Furthermore, a discounted cash flow model suggests the stock's intrinsic value could be as high as $63.33, significantly above its current trading price of $22.79.
CPRX Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes the financial performance of Catalyst Pharmaceuticals Inc. (CPRX), focusing on its profitability margins and efficiency ratios. It highlights CPRX's strong gross, operating, and net margins, along with its Return on Equity, and provides a comparative benchmark against competitors like ARQT and SUPN.
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Catalyst Pharmaceuticals Inc. (CPRX) rose 2.06% to $22.79 on Friday, defying a general market downturn where the NASDAQ Composite Index fell 2.01% and the Dow Jones Industrial Average fell 0.96%. This performance ended a two-day losing streak for the stock.
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
The article analyzes Catalyst Pharmaceuticals (CPRX) stock from a value investing perspective, highlighting its Zacks Rank #1 (Strong Buy) and an A grade for Value. It points out CPRX's attractive PEG ratio of 0.72 and P/CF ratio of 10.23, both favorable compared to industry averages, suggesting the stock may be undervalued. The analysis concludes that CPRX stands out as a strong value stock based on its valuation metrics and earnings outlook.
Catalyst Pharmaceuticals (NASDAQ: CPRX) FIRDAPSE patent trial pushed to May 2026
Catalyst Pharmaceuticals (CPRX) announced that the federal court has postponed the start of its patent bench trial against Hetero USA, Inc. The trial, concerning the validity of Catalyst’s FIRDAPSE patents expiring in 2032, 2034, and 2037, has been rescheduled from March 23, 2026, to May 18, 2026, extending the resolution timetable by nearly two months. This change, reported in an 8-K filing, is considered to have a moderate impact and neutral sentiment.
Patent trial on Catalyst (NASDAQ: CPRX) FIRDAPSE® patents delayed to May 18, 2026
Catalyst Pharmaceuticals, Inc. filed an amended 8-K/A report to correct a scrivener's error in a signature date, with no other substantive changes to its previous filing. The crucial update is the delay of a federal court bench trial concerning the validity of its FIRDAPSE® patents, which were set to expire in 2032, 2034, and 2037. The trial against Hetero USA, Inc. has been postponed from March 23, 2026, to May 18, 2026, impacting the timeline for resolution of its market exclusivity.
Catalyst Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Listing on NASDAQ
Catalyst Pharmaceuticals, Inc. announced a delay in the bench trial concerning the validity of its FIRDAPSE® patents, which protect its primary revenue-generating product. The trial, originally set for March 23, 2026, is now scheduled to begin on May 18, 2026. This legal update is critical for investors as the trial's outcome will heavily influence the company's market exclusivity and future revenue, potentially causing significant stock volatility.
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors
Catalyst Pharmaceuticals Inc. (CPRX) stock decreased by 2.23% on Wednesday, closing at $22.81. This underperformance occurred during a generally negative trading session, with both the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing declines. The stock's fall ended a two-day winning streak for Catalyst Pharmaceuticals.
Is Catalyst Pharmaceuticals (CPRX) Offering Value After Strong Multi‑Year Share Price Gains
Catalyst Pharmaceuticals (CPRX) is currently viewed as undervalued according to Simply Wall St's valuation framework. A Discounted Cash Flow (DCF) analysis suggests the stock is 63.6% undervalued, while its P/E ratio of 13.24x is significantly below the biotech industry average and its own Fair Ratio. This analysis indicates potential value for investors, despite recent share price fluctuations.
Fundsmith LLP Acquires 654,721 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
Fundsmith LLP increased its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 24.2% in the third quarter, acquiring an additional 654,721 shares to hold a total of 3,363,807 shares valued at $66.27 million. Wall Street analysts maintain a positive outlook on Catalyst Pharmaceuticals, with a consensus "Buy" rating and a target price of $34.00, supported by recent upgrades from firms like Citigroup and Zacks. The biopharmaceutical company, which focuses on rare neuromuscular, neurological, and metabolic diseases, is currently trading at $23.23 with a market capitalization of $2.84 billion.
Is Catalyst Pharmaceuticals (CPRX) Offering Value After Strong Multi‑Year Share Price Gains
Catalyst Pharmaceuticals (CPRX) has seen strong multi-year share price gains but is currently assessed as undervalued by Simply Wall St's valuation framework. Both a Discounted Cash Flow (DCF) analysis and Price-to-Earnings (P/E) ratio comparison suggest the stock is significantly undervalued, with the DCF model indicating a 63.6% undervaluation. The article encourages investors to explore these valuation methods and consider personal "Narratives" for a more tailored assessment of the company's future prospects.
Kennedy Capital Management LLC Grows Position in Catalyst Pharmaceuticals, Inc. $CPRX
Kennedy Capital Management LLC has increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5%, acquiring an additional 50,746 shares and bringing its total holdings to 1,060,207 shares valued at approximately $20.9 million. Other institutional investors have also adjusted their positions in CPRX, which currently has a market capitalization of $2.86 billion and a P/E ratio of 13.85. Analysts maintain a "Buy" consensus rating on the stock, with a target price of $34.00, following recent upgrades from firms like Wall Street Zen, Weiss Ratings, Citigroup, and Zacks Research.
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Weakness
Catalyst Pharmaceuticals (CPRX) has experienced recent share price weakness, trading at $23.39, but still shows a strong 1-year return of 12.07% and significant 5-year gains. The company appears undervalued with a P/E ratio of 13.3x, lower than the industry average, and a discounted cash flow (DCF) model suggesting a fair value of $63.70 per share. This analysis indicates a potential undervaluation for the rare disease specialist, offering an opportunity for investors after the recent dip.
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) appears to be a compelling value investment according to a detailed fundamental analysis. The company scores highly in price, financial condition, earnings, and expansion, suggesting it is currently undervalued by the market. Its robust financial health, strong earnings, and positive growth outlook provide a significant "margin of safety" for investors despite inherent risks in the biotechnology sector.
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount
Catalyst Pharmaceuticals (CPRX) is currently trading at a 20-33% discount according to fundamental metrics, though the author suggests it is more fairly valued when considering execution risk and patent cliffs. The company's valuation is heavily influenced by the outcome of a key litigation case regarding its drug FIRDAPSE, which could significantly alter its fair value. While the company exhibits strong fundamentals like high ROIC and a significant cash hoard, insider selling and the binary nature of the litigation suggest the current price reflects known risks rather than a deep undervaluation.
Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks
Amid heightened geopolitical tensions, market volatility, and inflation concerns, value investing becomes attractive as fundamentally strong companies may trade at discounted prices. This article identifies four low-PEG stocks—Air Lease (AL), National Energy Services Reunited (NESR), Catalyst Pharmaceuticals (CPRX), and JBT Marel Corporation (JBTM)—that fit specific value criteria, including a low PEG ratio, favorable Zacks Rank, and strong growth prospects. The PEG ratio is highlighted as a critical metric for investors seeking to avoid "value traps" by considering future earnings growth.
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount
Catalyst Pharmaceuticals (CPRX) exhibits strong fundamentals, including a 7.5% free cash flow yield and high ROIC, but its valuation is deeply tied to the outcome of the Hetero litigation concerning its primary drug, FIRDAPSE. While the company appears undervalued by 20-33% based on traditional metrics, insider selling suggests current prices might be seen as fair given the significant execution risks and patent cliff. The article provides a probability-weighted fair value of $29, but emphasizes the binary nature of the litigation and the need for successful new drug development or acquisitions to sustain growth beyond 2030-2035.
Neo Ivy Capital Management Sells 104,411 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
Neo Ivy Capital Management significantly reduced its stake in Catalyst Pharmaceuticals (CPRX) by selling over 104,000 shares, cutting its holdings by 83.1%. Simultaneously, Director Molly Harper also sold a large portion of her shares, reducing her position by over 91%. Despite this insider selling, equity analysts maintain a "Buy" rating on CPRX with a consensus price target of $34.00, and several firms have recently upgraded the stock.
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Catalyst Pharmaceuticals will present real-world findings on Duchenne muscular dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference. The company will showcase multiple poster presentations focusing on the real-world analysis of vamorolone in patients with DMD, covering aspects like concomitant cardiac medication use, healthcare resource utilization, and delayed respiratory decline. Additionally, Catalyst will sponsor an MDA Industry Forum with Santhera Pharmaceuticals dedicated to vamorolone.
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.0% After Raising Its 2026 Revenue Outlook And What’s Next
Catalyst Pharmaceuticals (CPRX) shares rose 5.0% after the company raised its 2026 revenue outlook to US$615 million to US$645 million, following strong 2025 results. This improved outlook, driven by FIRDAPSE and AGAMREE, reinforces the company's near-term growth story but is accompanied by ongoing legal and patent uncertainties surrounding FIRDAPSE exclusivity.
Intech Investment Management LLC Sells 46,656 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
Intech Investment Management LLC significantly reduced its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 46.2%, selling 46,656 shares but still holding 54,413 shares valued at $1.07 million. Despite this, other hedge funds increased their positions, and analysts generally rate CPRX as a "Buy" with a consensus price target of $34.00. The stock currently trades around $24.24, with institutional investors owning 79.22% and insiders 10.4% after a director's share sale.
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.0% After Raising Its 2026 Revenue Outlook And What’s Next
Catalyst Pharmaceuticals' stock rose 5.0% after the company raised its 2026 revenue outlook to US$615 million to US$645 million, following strong 2025 results. This positive revision underscores the success of its rare disease franchises, FIRDAPSE and AGAMREE, as key growth drivers. However, the company still faces risks related to potential generic competition for FIRDAPSE and a limited late-stage pipeline, which investors should consider alongside the improved financial projections.
Catalyst Pharmaceuticals Record 2025 Results Highlight Rare Disease Growth Story
Catalyst Pharmaceuticals reported record full-year and Q4 2025 results, driven by strong growth in its rare disease treatments, AGAMREE and FIRDAPSE. The company's focus on therapies for rare neurological conditions and strategic partnerships has positioned it for continued expansion, with 2026 revenue guidance set between US$615 million and US$645 million. Investors are watching for stable quarterly margins and effective execution on product uptake and business development in the specialized rare disease market.
Catalyst Pharmaceuticals Record 2025 Results Highlight Rare Disease Growth Story
Catalyst Pharmaceuticals reported record full-year and Q4 2025 results, driven by strong uptake of its rare disease treatments, AGAMREE and FIRDAPSE. The company's focus on therapies for rare neurological conditions and its strategic alliances are key to its growth story, despite a slight dip in Q4 net income. Investors are looking to 2026 revenue guidance and execution on product uptake and partnerships for continued growth.
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Catalyst Pharmaceuticals will present real-world findings on Duchenne muscular dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference through multiple poster presentations. The company will also host a vamorolone-focused symposium with Santhera Pharmaceuticals. These presentations and the symposium aim to provide clinical insights into AGAMREE®'s profile and its role in patient care for the Duchenne community.
How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 43.34%
Wall Street analysts project a potential upside of 43.3% for Catalyst Pharmaceuticals (CPRX), with a mean price target of $34.86, suggesting the stock could still see significant gains. While price targets alone can be misleading, strong agreement among analysts on upward earnings estimate revisions strengthens the optimistic outlook. The company also holds a Zacks Rank #1 (Strong Buy), further indicating its potential for near-term upside.
Catalyst Pharmaceuticals to Present Real-World Findings on Duchenne Muscular Dystrophy at 2026 MDA Conference
Catalyst Pharmaceuticals will present real-world findings on Duchenne Muscular Dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida, through multiple poster presentations and a sponsored Industry Forum. The presentations will focus on analyzing vamorolone's use, cardiac medication co-administration, and the impact of glucocorticoid treatment on healthcare resource utilization and respiratory decline in DMD patients. This participation aims to enhance patient care and advance research for the Duchenne community, highlighting the role of AGAMREE® in treatment.
Real-world Duchenne data: how a novel steroid is used in care
Catalyst Pharmaceuticals will present real-world data analyses of vamorolone in Duchenne muscular dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference. The presentations will cover topics like cardiac medication use with vamorolone, glucocorticoid treatment duration, and its association with delayed respiratory decline. Additionally, Catalyst will host an MDA Industry Forum focusing on clinical insights and long-term evidence generation for DMD patient care.
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Catalyst Pharmaceuticals will present real-world findings on Duchenne muscular dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference. The company will showcase multiple poster presentations focusing on vamorolone's impact on DMD patients and will also sponsor an MDA Industry Forum with Santhera Pharmaceuticals dedicated to vamorolone. This participation aims to expand real-world evidence and clinical insights for the Duchenne community.
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Catalyst Pharmaceuticals will present real-world findings regarding Duchenne muscular dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference, featuring multiple poster presentations. The company will also sponsor a vamorolone-focused industry forum in conjunction with Santhera Pharmaceuticals. These initiatives aim to highlight expanding real-world evidence and clinical insights for DMD treatment, particularly concerning AGAMREE®'s profile and patient care.
American Century Companies Inc. Purchases 770,198 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
American Century Companies Inc. increased its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 43.8%, acquiring an additional 770,198 shares to hold a total of 2,528,186 shares valued at $49.8 million. This move highlights significant institutional interest, as other large investors like Goldman Sachs, UBS, and RBC have also increased their positions, contributing to 79.22% institutional ownership. Wall Street analysts maintain a bullish outlook, with a consensus "Buy" rating and an average price target of $34, with Citigroup recently raising its target to $35.
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Shares of Catalyst Pharmaceuticals Inc. (CPRX) fell 1.50% to $24.32 on Thursday, despite the company's stock outperforming its competitors. This decline occurred during an overall rough trading session for the stock market, with both the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing losses. The stock's fall ended a three-day winning streak.
Zacks Research Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Strong-Buy
Zacks Research has upgraded Catalyst Pharmaceuticals (CPRX) to a "Strong-Buy" rating from "hold," joining other firms that have issued positive ratings, resulting in a consensus "Buy" rating and a $34.00 target price. The company's shares traded up 3.2% at market open, and institutional ownership stands at approximately 79.22%, following significant purchases by major investment firms. Insider transactions show Director Molly Harper sold a substantial portion of her shares in December, though insiders still hold 10.4% of the stock.
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Catalyst Pharmaceuticals will present real-world findings in Duchenne muscular dystrophy (DMD) through multiple poster presentations at the 2026 MDA Clinical & Scientific Conference. The company will also sponsor a vamorolone-focused industry forum, highlighting clinical insights about AGAMREE® and its role in patient care. The presentations will cover topics such as concomitant cardiac medication use, glucocorticoid treatment duration, and delayed respiratory decline in DMD patients.
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Record 2025 Earnings And New 2026 Revenue Guidance
Catalyst Pharmaceuticals (CPRX) recently reported record Q4 and full-year 2025 earnings and provided strong 2026 revenue guidance of US$615 million to US$645 million, yet its share price performance has been relatively modest. The company's valuation, based on rare disease revenue and margin assumptions, suggests it could be 30.2% undervalued, with a fair value estimated at $34.29 against a recent close of $23.92. However, risks such as FIRDAPSE concentration, patent litigation, and FYCOMPA’s loss of exclusivity could impact these optimistic assumptions.
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Record 2025 Earnings And New 2026 Revenue Guidance
Catalyst Pharmaceuticals (CPRX) reported record Q4 and full-year 2025 results, driven by strong product revenues, and issued 2026 revenue guidance between US$615 million and US$645 million. Despite this positive news, the stock's recent share price performance has been modest. Analysts suggest the company is undervalued, with a fair value of $34.29 compared to a recent close of $23.92, largely due to strong rare disease revenue and margin assumptions, though risks like patent litigation remain.
